Management of Opioid Use Disorder: See Practice Guideline 900.5034

Buprenorphine Patch (Butrans) is NON-formulary as of 2017

Subcutaneous buprenorphine extended‐release:

• • SUBLOCADE® is Restricted as below:
    • Ambulatory:  For clinics (typically primary care, Pain Clinics and Project Nurture); due to REMS program, only to be filled through Legacy Apothecary. 
    • Inpatient: Non-formulary

• • BRIXADI® is Formulary Restricted as below:
    • Weekly Formulation is limited to outpatient clinics, PES (Psychiatric Emergency Services), and ESUDS (Emergency Substance Use Disorder Service).
    • Monthly formulation will be limited to clinic use. It won’t be available during hospital stay at this time.
    • Planned transition to sublingual buprenorphine during inpatient stays.

• Micromedex
• CareNotes
• UpToDate
• Facts & Comparisons
• MedLinePlus (Patient Information)